Our lawyers

Back

Marino Baldi

Senior Counsel

Position: Senior Counsel
Practice Areas: Competition & Regulatory Matters , Corporate & M&A
Field-Display: Competition & Regulatory Matters Team , Corporate & M&A Team , COVID19

Dr Marino Baldi advises on Swiss and international business law, particularly antitrust and competition law, the law of international trade relations, international investments and on European single market law. As the Swiss ambassador and a member of SECO’s Board of Directors, he led many international trade negotiations and played a critically important part in the current competition and single market law. He was a member of the Swiss Competition Commission and teaches European and international business law at the University of Zurich.

E-Mail

+41 31 327 54 54

Linkedin

VCard

Practice Areas

  • Competition & Regulatory Matters
  • Corporate & M&A

Education

  • University of St. Gallen (Dr. oec., 1972; lic. oec., 1966)
  • University of St. Gallen (research assistant in business and trade law, 1966-69)
  • University of Brussels (lic. en droit européen, 1968)

Languages

  • German
  • English
  • French
  • Italian

Membership

  • Studienvereinigung Kartellrecht (Competition Lawyers Association)
  • Fachgruppe Kartellrecht des Bernischen Anwaltsverbands (Competition Law Panel of Bernese Bar Association)
  • International Bar Association
  • World Trade Institute, Senior Research Fellow

Assistant

Nicole Stofer
+41 31 327 54 23
nicole.stofer@prager-dreifuss.com

Publications

Subject: Competition & Regulatory Matters
Autor: Marino Baldi
Paper: NZZ
Reading time: 2 Min

UBS - Secure competition

Guest commentary by Marino Baldi and Felix Schraner. Marino Baldi is Of Counsel at Prager Dreifuss; Felix Schraner is Partner at Ixar Legal AG.

Subject: Health and Medical Law
Autor: Marino Baldi, Bernhard C. Lauterburg, Andrea Schütz, Philipp E. Zurkinden

GCR Life Sciences - Switzerland

A stable and comprehensible legal framework is of great importance, not only in crisis situations, but in general. Legal uncertainties are poison for the supply of a country with important medical goods. The life sciences sector has so far not raised any major competition law issues in Switzerland. Yet, recent jurisprudence as well as enacted and planned legislative amendments are not free of contradictions and ambiguities. The lack of an update of the Mutual Recognition Agreement and the related status of Switzerland as a third country vis-à-vis the EU brought additional uncertainties. The authors provide an overview of the current regulatory environment and discuss the implications of planned legislative changes.

Subject: Corporate News
Autor: Marino Baldi

Juristische Publikationen von Dr. Marino Baldi

Autor: Marino Baldi
Paper: NZZ

Anti-trust law must not be undermined

Autor: Marino Baldi
Paper: AJP/PJA

20 Jahre - und kein bisschen weiter?

Autor: Marino Baldi
Paper: AJP/PJA

Kartellgesetzrevision: Vom Widersinn der Teilkartellverbote

Autor: Marino Baldi
Paper: AJP/PJA

More Modesty and Honesty in International Investment Law!